188053-29-4

Usage

Chemical class

phenylpropylamines

Use

precursor in the synthesis of pharmaceutical drugs (e.g. amphetamines, designer drugs)

Physical form

colorless liquid

Odor

faint amine odor

Solubility

soluble in water and organic solvents

Therapeutic properties

neuroprotective and anti-inflammatory agent

Potential risks

potential for abuse and harmful if not used under proper supervision and regulation.

Upstream product

• 108971-52-4 benzyl-[2-(2-methoxy-phenyl)-propyl]-amine 
• 612-15-7 o-methoxystyrene 
• 103108-05-0 2-(2-methoxyphenyl)propanal 
• 1476076-15-9 2-(2-(2-methoxyphenyl)propyl)isoindoline-1,3-dione 
• 94013-66-8 2-(2-methoxyphenyl)propan-1-ol 
• 81616-80-0 (S)-2(2-methoxyphenyl)propionic acid 
• 93-25-4 2-methoxyphenylacetic acid 
• 103855-91-0 3-(2-methoxy-phenyl)-butyric acid amide 

Downstream Products

• 1476076-16-0 6-chloro-N-(2-(2-methoxyphenyl)propyl)pyrimidin-4-amine 
• 1476076-17-1 N-(2-(2-methoxyphenyl)propyl)-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrimidin-4-amine 
• 1476749-06-0 (S)-N-(2-(2-methoxyphenyl)propyl)-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrimidin-4-amine 
• 108971-52-4 benzyl-[2-(2-methoxy-phenyl)-propyl]-amine 
• 14959-82-1 2-(β-Amino-isopropyl)-phenol 

Relevant academic research and scientific papers

Dynamic kinetic resolution of 2-phenylpropanal derivatives to yield β-chiral primary amines via bioamination

The amination of racemic α-chiral aldehydes, 2-phenylpropanal derivatives, was investigated employing ω-transaminases. By medium and substrate engineering the optical purity of the resulting β-chiral chiral amine could be enhanced to reach optical purities up to 99% ee. Using enantiocomplementary ω-transaminases allowed us to access the (R)- as well as the (S)-enantiomer in most cases. It is important to note that the stereopreference of the ω-transaminases found for α-chiral aldehydes did not correlate with the stereopreference previously observed for the amination of methyl ketones. In one case the stereopreference switched even upon exchanging a methyl substituent to a methoxy group.

DNA-PK INHIBITORS

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.